Exploring parkinson-associated kinases for CRISPR/cas9-based gene editing: beyond alpha-synuclein

HM Mansour, AS El-Khatib - Ageing Research Reviews, 2023 - Elsevier
Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by the
loss of dopaminergic neurons in the substania nigra (SN) and is associated with progressive …

FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders

A Lui, J Vanleuven, D Perekopskiy, D Liu, D Xu… - Pharmaceuticals, 2022 - mdpi.com
Cancers and neurological disorders are two major types of diseases. We previously
developed a new concept termed “Aberrant Cell Cycle Diseases”(ACCD), revealing that …

Sequence-based machine learning method for predicting the effects of phosphorylation on protein-protein interactions

X Hong, J Lv, Z Li, Y Xiong, J Zhang… - International Journal of …, 2023 - Elsevier
Protein phosphorylation, catalyzed by kinases, is an important biochemical process, which
plays an essential role in multiple cell signaling pathways. Meanwhile, protein-protein …

PARIS undergoes liquid–liquid phase separation and poly (ADP‐ribose)‐mediated solidification

H Kang, S Park, A Jo, X Mao, M Kumar, CH Park… - EMBO …, 2023 - embopress.org
ZNF746 was identified as parkin‐interacting substrate (PARIS). Investigating its
pathophysiological properties, we find that PARIS undergoes liquid–liquid phase separation …

[HTML][HTML] Stem cell transplantation for Parkinson's disease: Current challenges and perspectives

X Zeng, H Qin - Aging and Disease, 2022 - ncbi.nlm.nih.gov
Parkinson's disease is the second most common form of neurodegeneration, and it poses a
major threat to the quality of life of older adults. Stem cell transplantation, which has attracted …

Cell biology of Parkin: clues to the development of new therapeutics for Parkinson's disease

J Patel, N Panicker, VL Dawson, TM Dawson - CNS drugs, 2022 - Springer
Parkinson's disease is the second most prevalent neurodegenerative disease and
contributes significantly to morbidity globally. Currently, no disease-modifying therapies exist …

[HTML][HTML] Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson's disease

JY Shin, B Lee, S Ham, JH Kim, H Kim, H Kim… - Biomedicine & …, 2022 - Elsevier
The aggregation of aminoacyl transfer RNA synthetase complex-interacting multifunctional
protein-2 (AIMP2) accelerates α-synuclein aggregation via direct interaction, leading to …

ATF4-activated parkin induction contributes to deferasirox-mediated cytoprotection in Parkinson's disease

S Ham, JH Kim, H Kim, JY Shin, Y Lee - Toxicological Research, 2023 - Springer
The E3 ubiquitin ligase parkin plays neuroprotective functions in the brain and the deficits of
parkin's ligase function in Parkinson's disease (PD) is associated with reduced survival of …

[HTML][HTML] The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model

T Marín, C Valls, C Jerez, T Huerta, D Elgueta… - IBRO Neuroscience …, 2022 - Elsevier
Parkinson's disease is the second most common neurodegenerative disorder. Although it is
clear that dopaminergic neurons degenerate, the underlying molecular mechanisms are still …

Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons

J Yu, Z Zhao, Y Li, J Chen, N Huang, Y Luo - Heliyon, 2024 - cell.com
Parkinson's disease (PD) is a neurodegenerative disorder with motor symptoms like
bradykinesia, tremors, and balance issues. The pathology is recognized by progressively …